Gita Patel

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Alasdair Munro, Shuo Feng, Leila Janani et al. · The Lancet Infectious Diseases · 2022 · 177 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections

Gita Patel, Nimish Patel, Asma Lat et al. · Diagnostic Microbiology and Infectious Disease · 2009 · 69 citations

Pharmacy, Infectious Diseases, Microbiology +12

Antimicrobial stewardship: A collaborative partnership between infection preventionists and health care epidemiologists

Julia Moody, Sara E. Cosgrove, Russell N. Olmsted et al. · American Journal of Infection Control · 2012 · 61 citations

Pharmacy, Infectious Disease Control, Infectious Diseases +17

Long‐term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high‐dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments

Caroline Alvares, Faith E. Davies, C Horton et al. · British Journal of Haematology · 2005 · 49 citations · Full text

Medicine, Hematology, Pharmacotherapy +12

Comparison of the in vitro activities of quassinoids with activity against Plasmodium falciparum, anisomycin and some other inhibitors of eukaryotic protein synthesis

Rosemary Ekong, Geoffrey C. Kirby, Gita Patel et al. · Biochemical Pharmacology · 1990 · 46 citations

Medicine, Medicinal Chemistry, Pharmacology +14